Protagenic Therapeutics, Inc.\new

OTC:PTIXOTC:PTIXW

Pharmaceutical Preparations·NEW YORK, NY

CFO

Arrow Alexander K.

Summary Financials

Revenue

FY 2024

Adj. EBITDA

-$4.5M

FY 2024

Net Income

-$5.0M

FY 2024

EPS (Diluted)

-$1.15

FY 2024

Stock Price

$0.74

-43.1%

2026-01-02

52W Range

$0.70 – $14.28

P/E Ratio

-0.6x

Market Cap

$1.3M

Cash

$798,623

FY 2020

Total Debt

$325,591

FY 2015

Net Cash

$473,032

FY 2015

Enterprise Value

$866,521.92

Debt / EBITDA

0.1x

FY 2024

EV / EBITDA

-0.2x

Employees

—

Revenue

FY 2024

Adj. EBITDA

-$4.5M

FY 2024

Net Income

-$5.0M

FY 2024

EPS (Diluted)

-$1.15

FY 2024

Stock Price

$0.74

-43.1%

2026-01-02

52W Range

$0.70 – $14.28

P/E Ratio

-0.6x

Market Cap

$1.3M

Cash

$798,623

FY 2020

Total Debt

$325,591

FY 2015

Net Cash

$473,032

FY 2015

Enterprise Value

$866,521.92

Debt / EBITDA

0.1x

FY 2024

EV / EBITDA

-0.2x

Employees

—